Taub Institute: Genomics Core
AN NIA-FUNDED ALZHEIMER'S DISEASE RESEARCH CENTER

 

Columbia University
Medical Center
Neurological Institute

710 West 168th Street, 3rd floor
(212) 305-1818


bottom bar
top
make an appointment

Clinical Trials

Clinical Trials Currently Recruiting



PMild Cognitive Impairment/ Alzheimer’s Disease: TAURIEL RO7105705 (anti-tau) (Genentech, Inc.)
A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients with Prodromal to Mild Alzheimer's Disease.
Phase 2. Intravenous Medication. Duration: about 73 weeks. NCT03289143.
Mild Cognitive Impairment due to Alzheimer’s Disease (AD)/Mild Alzheimer’s Disease (AD). MMSE: ≥20. Age: 50-80.
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

Mild Cognitive Impairment/ Alzheimer’s Disease: MISSION AD elenbecestat (E2609) (Eisai Co.)
A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease.
Phase 3. Oral Medication. Once daily. Duration: 24 months. NCT02956486.
Mild Cognitive Impairment due to Alzheimer’s Disease (AD)/Mild Alzheimer’s Disease (AD). MMSE: ≥24. Age: 50-85.
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

Mild Cognitive Impairment/ Alzheimer’s Disease: DISCOVER Posiphen® (QR Pharma Inc.)
Safety, Tolerability, PK and PD of Posiphen® in Subjects with Early Alzheimer’s Disease.
Phase 1/2. Oral Medication. Three times daily. Duration: about 1 month. NCT02925650.
Mild Cognitive Impairment due to Alzheimer’s Disease (AD)/Mild Alzheimer’s Disease (AD). MMSE: 21-27. Age: 55-85.
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

Mild Cognitive Impairment: Computerized Cognitive Training (NIA)
Cognitive Training and Neuroplasticity in Mild Cognitive Impairment.
Interventional Trial. Computerized Cognitive Training. Duration: 78 weeks. NCT03205709.
Mild Cognitive Impairment (MCI). MMSE 23-30. Ages 55-95.
(Dr. Devanand) Call Jessica D’Antonio 646-774-8674

Alzheimer’s disease: VALAD valacyclovir (NIH/NIA)
Anti-viral therapy in Alzheimer’s disease.
Phase 2. Oral Medication. Twice daily. Duration: 78 Weeks (18 months). NCT03282916.
Mild Alzheimer’s disease (AD); positive screening tests results for antibodies to HSV1 or HSV2. MMSE: 20-28. Age 55-95.
(Dr. Devanand) Call Julianna Pollina 646-774-8638

Alzheimer’s Disease: lithium (NIH/NIA)
Treatment of Psychosis and Agitation in Alzheimer’s Disease.
Phase 2. Oral Medication. Once daily. Duration: 12 weeks. NCT02129348.
Possible or Probable Alzheimer’s Disease (AD). MMSE: 5-26. Age: 55-95.
(Dr. Devanand) Call Laura Simonpearson 646-774-8671

Alzheimer's Disease: escitalopram (NIA)
Escitalopram for Agitation in Alzheimer’s Disease.
Phase 3. Combination intervention; Psychosocial Intervention and Oral Medication. Duration: 24 Weeks (6 months). NCT03108846.
Alzheimer's disease (AD) with agitation. MMSE: 5-28. Age 55-95.
(Dr. Devanand) Call Laura Simonpearson 646-774-8671

Frontotemporal Dementia: lithium (ADDF)
Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia.
Phase 2/3. Oral Medication. Once daily. Duration: 12 Weeks. NCT02862210.
Frontotemporal Dementia (FTD). MMSE: 5-26. Age: 40-85
(Dr. Huey) Call Hannah Silverman (212) 305-6284

Frontotemporal Dementia: FOXY
A Phase 2 Clinical Trial of Oxytocin for Frontotemporal Dementia.
Phase 2/3. Intranasal spray. Twice daily. Duration: 24 Weeks. NCT03260920.
Frontotemporal Dementia (FTD). MMSE: >10. Age: 30-80
(Dr. Huey) Call Hannah Silverman (212) 305-6284

Progressive Supranuclear Palsy: ARISE ABBV-8E12 (AbbVie)
A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy.
Phase 2. Intravenous Medication. Every 28 days. Duration: 52 weeks. NCT02985879.
Progressive Supranuclear Palsy (PSP). MMSE: ≥15. Age: 40-99.
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

Huntington’s Disease: SIGNAL (Vaccinex)
VX15/2503 Treatment for Huntington’s Disease.
Phase 2. Intravenous Medication. Duration: 12 or 16 months. NCT0248167.
Huntington’s Disease (HD). Age: >21. MoCa: >23.
(Dr. Marder) Call Paula Wasserman 212-305-4597, Ronda Clouse 212-305-2387

Observational Studies Currently Recruiting



Mild Cognitive Impairment/ Mild Alzheimer’s Disease/ Normal Cognition: ADNI3 (NIH/NIA)
Alzheimer’s Disease Neuroimaging Initiative 3
Duration: 2. NCT02854033
Mild Cognitive Impairment/Mild Alzheimer’s Disease/Normal Cognition. MMSE: ≥24 (CN and MCI) 20-24 (AD). Age: 55-90.
(Dr. Stern) Call Anton Kociolek 212-342-0522

Mild Cognitive Impairment: ADRC Project 1(NIH/NIA)
White Matter and Hippocampal Circuitry
Duration: 2 visits, 2.5hrs each visit.
Mild Cognitive Impairment (MCI). CDR 0 or 0.5. Age: ≥60.
(Dr. Brickman) Call Christiane Hale 646-317-4072

Mild Cognitive Impairment/ Mild Alzheimer’s Disease/ Normal Cognition: Inflammation Imaging in AD (NIH/NIA)
Imaging Inflammation in Elders with Different Clinical and Biomarker Profiles of Alzheimer’s Disease
Duration: 5 visits.
Mild Cognitive Impairment/Mild Alzheimer’s Disease/Normal Cognition. Age: ≥60.
(Dr. Kreisl) Call Aubrey Johnson 212-305-9079

Alzheimer’s Disease: Immune Response in AD (JPB Foundation)
Antigen Presentation and Lymphocyte Response in Alzheimer’s Disease
Duration: 1.5 hrs; 1 visit.
Early Alzheimer’s Disease. Age: ≥55. MoCa: ≤26.
(Dr. Marder) Call Betina Idnay 212-342-5615

Alzheimer’s Disease: DIAN (NIH/NIA)
Dominantly Inherited Alzheimer Network
Duration: Years. Every 1 to 3 years visits.
Family members of a person with AD (proband) due to PSEN1, PSEN2, or APP mutations. MMSE: any. Age: ≥18; younger but no more than 10 years younger than proband’s AAO.
(Dr. Noble) Call Dolly Reyes-Dumeyer 212-305-5953, Katie Neimeyer 212-305-5909

Alzheimer’s Disease: EFIGA (NIH/NIA)
Genetic Study of Alzheimer’s Disease in Caribbean Hispanics
Duration: 1.5 hours visit (in person). Visits are every 2 years for the duration of the study.
Hispanic families with multiple affected alive-siblings (2+) and an additional individual healthy or not, willing to participate. Age: Affected any age. Unaffected 50 or older.
(Dr. Mayeux) Call Angel Piriz 212-305-2309

Alzheimer’s Disease: LOAD (NIH/NIA)
Late Onset Alzheimer’s Disease
Duration: 1.5 hours visit (in person/over the phone). Every 2 years visit for the duration of the study.
Any ethnic background families with multiple affected alive-siblings (2+) and an additional individual healthy or not, willing to participate; Age: Affected any age. Unaffected 50 or older.
(Dr. Mayeux) Call Pedro Mena 212-305-2309, Izri Martinez (For African American participants) 212-305-2349

Alzheimer’s Disease: READR (NIH/NIA)
Resource for Early Onset Alzheimer’s Disease Research: Early Onset Alzheimer’s Disease Whole Genome Sequencing
The goal is to identify unknown mutations (other than APP, PSEN1 and PSEN2) Duration: 1.5 hours visit (in person/over the phone). Every 2 years visit for the duration of the study.
Age: Onset of memory problems before the age of 65.
(Dr. Reitz) Call Penelope Baez 201-640-4335

Alzheimer’s Disease: Naming Study (NIH/NINDS)
Assessment and Characterizationof Naming in Older Adults with Epilepsy and PAD
Duration: 1 visit. 90 minutes.
Probable Alzheimer’s Disease. MMSE: 19-25. Age: 56-90.
(Dr. Hamberger/Dr. Honig) Call Alicia Williams 212-305-1801

Subjective Cognitive Complaint: SCD Project (NIH/NIA)
Characterizing Subjective Cognitive Decline in Older Adults
Duration: 1 visit. 1.5hrs.
Subjective Cognitive Complaint. Age: ≥56.
(Dr. Cosentino) Call Jillian Joyce 212-342-1969

Dementia with Lewy Bodies: Targeting Lewy Body Pathology (NIH/NINDS)
Targeting Lewy Body Specific Pathology Using Biomarkers
Duration: 5 years.
Dementia with Lewy Bodies. Age: ≥65.
(Dr. Marder/Dr. Honig) Call Helen Mejia-Santana 212- 305-9183, Martha Orbe Reilly 212-305-8873

Frontotemporal Lobar Degeneration: ARTFL (UCSF/NCATS/NINDS)
Advancing Research and Treatment for Frontotemporal Lobar Degeneration.
Observational and a treatment registry. NCT02365922.
Individuals and families with a +FH of Frontotemporal Lobar Degeneration (FTLD). Age: 18-85.
(Dr. Huey) Call Masood Manoochehri 212-305-5710

Familial Frontotemporal Dementia: LEFFTDS
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects.
Duration: 5 years. NCT02372773.
Families with at least one member with known MAPT, PGRN, and C9ORF72 genetic mutation. Age: ≥18.
(Dr. Huey) Call Masood Manoochehri 212-305-5710

Frontotemporal Lobar Degeneration: MAPT Family Study
Examination of the earliest symptoms and biomarkers of FTLD MAPT carriers.
Members of families with a MAPT mutation. Duration: 5 years.
(Dr. Huey) Call Gayathri Cheran 212-305-1561

Programs Currently Recruiting


Arts and Minds
The Studio Museum in Harlem, New York Historical Society, and El Museo del Barrio
Excluded: persons with depression (only), cognitively normal persons, and patients with dementia in whom agitation is severe and dominating care. Spanish-speakers are welcome. Participants will explore the world of art and culture in these interactive 75-minute programs.
(Dr. Noble) Call Carolyn Halpin-Healy 646-755-3726

bottom bar